Peptides Academy
CJC-1295 with DAC (Drug Affinity Complex)
Research-Grade
CJC-1295 with DAC is a tetrasubstituted analog of human growth-hormone-releasing factor (GRF) 1-29 with a maleimidopropionamide-modified lysine added at the C-terminus. This reactive group lets the peptide bind to serum albumin after injection: in rats, CJC-1295 was detected on the albumin band within 15 minutes and remained in circulation beyond 24 hours, and it produced a four-fold larger GH response than unmodified GRF(1-29). In two randomized, placebo-controlled, ascending-dose trials in healthy adults aged 21–61 (Teichman et al., 2006), a single subcutaneous injection increased mean GH 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9–11 days. The estimated half-life was 5.8–8.1 days, and after multiple weekly or every-two-week doses IGF-1 stayed above baseline for up to 28 days. No serious adverse reactions were reported, and doses of 30 or 60 mcg/kg were described as relatively well tolerated. Despite continuous GHRH-receptor stimulation, GH release stays pulsatile: in healthy men sampled overnight one week after 60 or 90 mcg/kg, the frequency and size of GH pulses were unchanged, while trough GH rose about 7.5-fold, mean GH 46% and IGF-1 45%. In GHRH-knockout mice, daily CJC-1295 normalized growth and body composition. CJC-1295 is not an approved medicine; human data come from small short-term studies, and the FDA lists CJC-1295 among bulk drug substances reviewed for compounding safety risks.
Specifications
| Origin / Manufacturer | Synthetic (GHRH analog with albumin-binding DAC linker) |
| Active Components | CJC-1295 with DAC (MPA-modified GRF 1-29) |
| Storage | Lyophilized: room temperature. Reconstituted: 2–8°C |
| Shelf Life | Lyophilized 24+ months; reconstituted 14–21 days refrigerated |
| Form Factor | Lyophilized powder (2 mg or 5 mg vial) |
Frequently Asked Questions
Sources & References
Every clinical claim on this page traces to a primary peer-reviewed source.
- 1Teichman SL, Neale A, Lawrence B, et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536 PMID:16352683
- 2Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-7. doi:10.1210/jc.2006-1702 PMID:17018654
- 3Jetté L, Léger R, Thibaudeau K, et al.. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. doi:10.1210/en.2004-1286 PMID:15817669
- 4Alba M, Fintini D, Sagazio A, et al.. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology. Endocrinology and Metabolism. 2006;291(6):E1290-4. doi:10.1152/ajpendo.00201.2006 PMID:16822960
- 5Bowers CY, Reynolds GA, Durham D, et al.. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. The Journal of Clinical Endocrinology and Metabolism. 1990;70(4):975-82. doi:10.1210/jcem-70-4-975 PMID:2108187
- 6U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA Human Drug Compounding. 2026.
Reviewed by
Clinical Research Review Board
Pharmacology & Endocrinology Review
All clinical claims cross-checked against primary sources. Read our editorial policy →
Related Peptides
CJC-1295 + Ipamorelin
Research-Grade
The most widely used GHRH + GHRP stack — CJC-1295 extends GHRH half-life while Ipamorelin selectively amplifies GH pulses without disturbing cortisol or prolactin.
CJC-1295 No DAC (Mod GRF 1-29)
Research-Grade
A tetrasubstituted GHRH (1-29) analog — CJC-1295 without the albumin-binding Drug Affinity Complex, often sold as Modified GRF 1-29; it has very little published human data and is research-only in the US.
Ibutamoren (MK-677)
Research-Grade
An oral, non-peptide growth hormone secretagogue that mimics ghrelin at the GHSR-1a receptor — produces sustained GH and IGF-1 elevation without injections. Extensively studied in human trials.
Ipamorelin
Research-Grade
The most selective GHRP (growth-hormone-releasing peptide) — amplifies GH pulses via ghrelin/GHSR receptor without meaningful cortisol, prolactin, or aldosterone crosstalk.
Sermorelin
Research-Grade
The first synthetic GHRH analog approved for clinical use — GHRH (1-29) NH₂, the minimum active sequence. Shorter-acting than tesamorelin or CJC-1295.
Tesamorelin
Egrifta
FDA-approved synthetic GHRH analog (Egrifta) indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy; also studied in HIV-associated fatty liver disease and cognition in older adults.